KUMULUS-VAPE
28.5.2019 05:59:06 CEST | Business Wire | Press release
At 11.30 am this Tuesday, May 28 2019, shares in Kumulus Vape (ISIN: FR0013419876 - symbol: MLVAP) will be listed for the first time on the Euronext Access™ market in Paris (by technical admission). Kumulus Vape is an e-merchant specializing in the sale of electronic cigarettes and related 'vaping' products (equipment, e-liquids and accessories).
The listing on the Paris stock exchange is a first for European vape companies, marking a new milestone in the performance trajectory of the company from Lyon, a pioneer in its market in an active phase of development. The aim of this move is to enable Kumulus Vape to raise brand awareness and strengthen its presence on the domestic market.
55,000 shares will be offered for sale on the first day of market trading. This admission to the Euronext Access™ market constitutes a first step, prior to a possible transfer of Kumulus Vape shares to the Euronext Growth® market. The company seeks to introduce a dynamic of shares changing hands that could account for between 5 and 10% of the capital.
Established in 2012, Kumulus Vape is one of the main French online sites for the sale of vaping products (equipment, e-liquid, DIY1 ). With its broad range, comprising over 6,000 items, it offers products for both 'beginners' and vaping experts. As a committed player in combating tobacco and an advocate for the vaping sector, Kumulus Vape offers an unequalled choice of high-performing vaping products at low prices.
In 2018, Kumulus Vape's turnover was €6.5 million, up 116% on 2017. The EBITDA exceeded the €400,000 mark (+128% on 2017), with a net income of nearly €300,000 (+106%). In the first quarter of 2019, turnover rose by 96% to €2.3 million.
Kumulus Vape has a clear aim: to become one of the French leaders in 100% e-commerce vaping in the next three years.
Operating procedures
Listing market:
Euronext Access™
ISIN
:
FR0013419876
Symbol
: MLVAP
Registration procedure
:
technical admission
Number of shares in company capital
:
1,988,000
Number of shares sold on the day of listing
: 55,000
Sale
price per share
: €2.12
Valuation at time of listing
:
€4,214,560
Start of trading
: May 28, 2019
Eligible
for PEA (equity savings plan) and SME PEA
: yes
The operation does not require authorization from the French Financial Markets Authority (AMF). The information document has therefore not been approved by the AMF. The information document is available free of charge from the head office of Kumulus Vape. It may be downloaded from www.kumulusvape.fr/investisseurs . Please note that companies admitted to Euronext Access are not subject to the same rules as companies on the regulated market. Instead, they are subject to a smaller set of rules that is suitable for small businesses experiencing growth. The risk associated with an investment on Euronext Access may therefore be greater than investing in a company on the regulated market.
Partners in the operation
|
Atout Capital |
Consultant and listing sponsor |
|
|
Lamy Lexel |
Legal advice |
|
|
Mazars |
Auditors |
|
|
Actifin |
Financial communications |
|
About Kumulus Vape
Established in 2012, Kumulus Vape is one of the leading French distributors of e-cigarettes and e-liquids . With www.kumulusvape.fr , its website for individuals, and its wholesale business for specialist boutiques, the Company is positioned on both the B2C and B2B markets. Kumulus Vape's turnover rose to €6.5 million in 2018, representing a growth of 116% on 2017. Kumulus Vape is based in Corbas, just a few minutes from the south of Lyon, and currently has about 25 employees.
1 Do It Yourself: e-liquid base that people can use to create their own blends
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005309/en/
Contact:
KUMULUS VAPE Director of Communications Vincent Baudoin v.baudoin@kumulusvape.fr Tel.: 06 10 84 52 59
ACTIFIN Press relations Aminata Doucouré adoucoure@actifin.fr Tel.: 01 56 88 11 23
ACTIFIN Financial communications Julien Mouret jmouret@actifin.fr Tel.: 01 56 88 11 14
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom